Development of a new inhibitor of BCR-ABL tyrosine kinase is necessary for the treatment of chronic myeloid leukemia (CML) because of increasing resistance and tolerance to Imatinid efforts. Herein, we reported Plumbagin can significantly inhibit the growth of CML. The results revealed that Plumbagin inhitbited TCCY and TCCY/T315I cells with IC50 values 3 μM and 2.1 μM, respectively. Plumbagin also showed anti-proliferative effects on both the wide type Ba/F3 and the BCR-ABL-transfected Ba/F3 cells with a range of IC50 from 3.2 to 3.8 μM. In addition, Plumbagin induced the apoptosis of CML cells. That would provide a new and potential drug as a chemotherapy medication in the treatment of Imatinid -resistant CML.